Eli Lilly is expanding the Indianapolis-based company’s footprint in Indiana through a $2.1 billion investment.
Bacteria in Antarctica have been discovered with genes that give them natural antibiotic and antimicrobial resistance and have the potential to spread out of the polar regions, according to scientists in Chile.
The ongoing COVID-19 pandemic, the war in Ukraine, rising fuel costs, manufacturing concerns and the ripple of other global events have led to supply chain issues across the world that, in the United States, has been most recently highlighted by a shortage of baby formula.
North Korea on May 21 reported more than 200,000 new patients suffering from fever for a fifth consecutive day, as the country fought its first confirmed coronavirus outbreak.
Infection with adenovirus, a common childhood virus, is the leading hypothesis for recent cases of severe hepatitis of unknown origin in children that have led to at least six deaths, U.S. health officials said on May 20.
The U.S. Food and Drug Administration approved Sanofi’s Dupixent (dupilumab) 300 mg weekly to treat patients with eosinophilic esophagitis (EoE) aged 12 years and older, weighing at least 40 kg. With this approval, Dupixent is the first and only medicine specifically indicated to treat EoE in the United States.
The World Health Organization was due to hold an emergency meeting on May 20 to discuss the recent outbreak of monkeypox, a viral infection more common to west and central Africa, after more than 100 cases were confirmed or suspected in Europe.
A smattering of monkeypox cases in Britain prompted authorities to offer a smallpox vaccine to some healthcare workers and others who may have been exposed, as a handful more cases were confirmed in parts of Europe.
The Massachusetts Department of Public Health on May 17 said it had confirmed a single case of monkeypox virus infection in a man who had recently traveled to Canada.
Valneva SE confirmed that the European Medicines Agency accepted the filing of a marketing authorization application (MAA) for the specialty vaccine company’s inactivated, whole-virus COVID-19 vaccine candidate, VLA2001.